Short answer
Neurogene Inc. (NGNE) filed its Q2 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$34M
- −56.6% YoY · −11.5% QoQ
- EPS (diluted)
- −$1.53
- −47.1% YoY · −10.1% QoQ
Source: XBRL data from the Neurogene Inc. (NGNE) Q2 2026 10-Q on SEC EDGAR. USD.
Neurogene Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No commercial revenue; net loss $65.4M for six months ended June 30, 2026 vs $44.7M YoY
- Cash, equivalents and short-term investments $225.4M at June 30, 2026
- July 2, 2026 public offering generated $134.8M net proceeds
- Cash runway expected into first quarter of 2029 following offering
- Top-line Embolden trial results expected second half of 2027; macroeconomic and supply-chain risks remain
Risk Factors
- Newly triggered program risk: FDA denial of NGN-101’s RMAT designation precludes the streamlined registrational pathway, forcing program reevaluation
- Most materially updated clinical risk: NGN-401 Embolden trial dosing completed in the second quarter of 2026, but regulatory approval remains uncertain
- Regulatory risk: Gene therapy approval requirements remain rigorous, complex, uncertain and subject to change
- Operational risk: NGN-401 dependence concentrates near-term execution on the company’s lead program
- Financial risk: Cumulative net loss reached $418.1 million through June 30, 2026, with cash expected to fund operations into the first quarter of 2029
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Neurogene Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.